Tatva Chintan Pharma Chem Limited
Fundamental Score
Tatva Chintan Pharma Chem Limited Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of TATVA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (17.54%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Robust Profit Growth (1603.03%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (47.95%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Conservative Debt Levels (D/E: 0.11)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (15.20x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (72.02%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
10 factors identified
Below-Average Return on Equity (0.78%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (1.20%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Premium Valuation Risk (P/E: 189.69x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Weak Earnings Growth (-44.61% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-31.41% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Negative Free Cash Flow (₹-327.00 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 7.27%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Financial Statements
Comprehensive financial data for Tatva Chintan Pharma Chem Limited
About TATVA
Business Overview
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
Company Details
Key Leadership
Corporate Events
TATVA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Tatva Chintan Pharma Chem Limited (TATVA)?
As of 29 Jan 2026, 10:39 am IST, Tatva Chintan Pharma Chem Limited (TATVA) is currently trading at ₹1109.30. The stock has a market capitalization of ₹3.37K (Cr).
Is TATVA share price Overvalued or Undervalued?
TATVA is currently trading at a P/E ratio of 189.69x, compared to the industry average of 29.20x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Tatva Chintan Pharma Chem Limited share price?
Key factors influencing TATVA's price include its quarterly earnings growth (Sales Growth: 47.95%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Tatva Chintan Pharma Chem Limited a good stock for long-term investment?
Tatva Chintan Pharma Chem Limited shows a 5-year Profit Growth of -31.41% and an ROE of 0.78%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.11 before investing.
How does Tatva Chintan Pharma Chem Limited compare with its industry peers?
Tatva Chintan Pharma Chem Limited competes with major peers in the Specialty Chemicals. Investors should compare TATVA's P/E of 189.69x and ROE of 0.78% against the industry averages to determine its competitive standing.
What is the P/E ratio of TATVA and what does it mean?
TATVA has a P/E ratio of 189.69x compared to the industry average of 29.20x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹190 for every ₹1 of annual earnings.
How is TATVA performing according to Bull Run's analysis?
TATVA has a Bull Run fundamental score of 37.5/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does TATVA belong to?
TATVA operates in the Specialty Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Tatva Chintan Pharma Chem Limited.
What is Return on Equity (ROE) and why is it important for TATVA?
TATVA has an ROE of 0.78%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Tatva Chintan Pharma Chem Limited generates profits from shareholders' equity.
How is TATVA's debt-to-equity ratio and what does it indicate?
TATVA has a debt-to-equity ratio of 0.11, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is TATVA's dividend yield and is it a good dividend stock?
TATVA offers a dividend yield of 0.07%, which means you receive ₹0.07 annual dividend for every ₹100 invested.
How has TATVA grown over the past 5 years?
TATVA has achieved 5-year growth rates of: Sales Growth 7.77%, Profit Growth -31.41%, and EPS Growth -44.61%.
What is the promoter holding in TATVA and why does it matter?
Promoters hold 72.02% of TATVA shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is TATVA's market capitalization category?
TATVA has a market capitalization of ₹3365 crores, placing it in the Small-cap category.
How volatile is TATVA stock?
TATVA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for TATVA?
TATVA has a 52-week high of ₹N/A and low of ₹N/A.
What is TATVA's operating profit margin trend?
TATVA has a 5-year average Operating Profit Margin (OPM) of 17.54%, indicating the company's operational efficiency.
How is TATVA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 47.95% and YoY Profit Growth of 1603.03%.
What is the institutional holding pattern in TATVA?
TATVA has FII holding of 3.40% and DII holding of 3.87%. Significant institutional holding often suggests professional confidence in the stock.